Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Data Resource Profile: The New Zealand Integrated Data Infrastructure (IDI).

Milne BJ, Atkinson J, Blakely T, Day H, Douwes J, Gibb S, Nicolson M, Shackleton N, Sporle A, Teng A.

Int J Epidemiol. 2019 Mar 15. pii: dyz054. doi: 10.1093/ije/dyz054. [Epub ahead of print] No abstract available.

PMID:
30879058
2.

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.

Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE.

Future Oncol. 2018 Oct;14(23):2415-2431. doi: 10.2217/fon-2018-0330. Epub 2018 Jul 6.

3.

PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.

Ghaneh P, Hanson R, Titman A, Lancaster G, Plumpton C, Lloyd-Williams H, Yeo ST, Edwards RT, Johnson C, Abu Hilal M, Higginson AP, Armstrong T, Smith A, Scarsbrook A, McKay C, Carter R, Sutcliffe RP, Bramhall S, Kocher HM, Cunningham D, Pereira SP, Davidson B, Chang D, Khan S, Zealley I, Sarker D, Al Sarireh B, Charnley R, Lobo D, Nicolson M, Halloran C, Raraty M, Sutton R, Vinjamuri S, Evans J, Campbell F, Deeks J, Sanghera B, Wong WL, Neoptolemos JP.

Health Technol Assess. 2018 Feb;22(7):1-114. doi: 10.3310/hta22070.

4.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
5.

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K.

Eur J Cancer. 2017 Sep;83:302-312. doi: 10.1016/j.ejca.2017.05.037. Epub 2017 Aug 4.

6.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

7.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

8.

Familial aggregation in developmental topographical disorientation (DTD).

Barclay SF, Burles F, Potocki K, Rancourt KM, Nicolson ML, Bech-Hansen NT, Iaria G.

Cogn Neuropsychol. 2016 Oct - Dec;33(7-8):388-397. doi: 10.1080/02643294.2016.1262835. Epub 2016 Dec 6.

PMID:
27923326
9.

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A.

J Clin Oncol. 2017 Feb;35(4):402-411. doi: 10.1200/JCO.2016.68.1841. Epub 2016 Nov 28.

PMID:
27893326
10.

Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.

Rosell R, Neninger E, Nicolson M, Huber RM, Thongprasert S, Parikh PM, D'Hondt E.

J Thorac Oncol. 2016 Nov;11(11):1954-1961. doi: 10.1016/j.jtho.2016.08.132. Epub 2016 Aug 24.

11.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

12.

Testing the Validity of Taxonic Schizotypy Using Genetic and Environmental Risk Variables.

Morton SE, O'Hare KJM, Maha JLK, Nicolson MP, Machado L, Topless R, Merriman TR, Linscott RJ.

Schizophr Bull. 2017 May 1;43(3):633-643. doi: 10.1093/schbul/sbw108.

13.

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.

Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y.

Histopathology. 2016 Aug;69(2):177-86. doi: 10.1111/his.12996. Epub 2016 Jun 30. Review. Erratum in: Histopathology. 2017 Jan;70(2):318.

14.

Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.

Kerr KM, Nicolson MC.

Arch Pathol Lab Med. 2016 Mar;140(3):249-54. doi: 10.5858/arpa.2015-0303-SA. Review.

PMID:
26927720
15.

Paternal and maternal ages have contrasting associations with self-reported schizophrenia liability.

Grattan RE, Morton SE, Warhurst ES, Parker TR, Nicolson MP, Maha JLK, Linscott RJ.

Schizophr Res. 2015 Dec;169(1-3):308-312. doi: 10.1016/j.schres.2015.09.018. Epub 2015 Sep 28.

PMID:
26421690
16.

The importance of health(ism): A focus group study of lesbian, gay, bisexual, pansexual, queer and transgender individuals' understandings of health.

Graham K, Treharne GJ, Ruzibiza C, Nicolson M.

J Health Psychol. 2017 Feb;22(2):237-247. doi: 10.1177/1359105315600236. Epub 2016 Jul 11.

PMID:
26311816
17.

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.

Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M.

Drugs. 2015 Aug;75(12):1335-48. doi: 10.1007/s40265-015-0434-6. Review.

18.

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

Lal R, Hillerdal GN, Shah RN, Crosse B, Thompson J, Nicolson M, Vikström A, Potter VA, Visseren-Grul C, Lorenzo M, D'yachkova Y, Bourayou N, Summers YJ.

Lung Cancer. 2015 Aug;89(2):154-60. doi: 10.1016/j.lungcan.2015.05.003. Epub 2015 May 12.

PMID:
26101013
19.

The impact of comorbidity upon determinants of outcome in patients with lung cancer.

Grose D, Morrison DS, Devereux G, Jones R, Sharma D, Selby C, Docherty K, McIntosh D, Nicolson M, McMillan DC, Milroy R; Scottish Lung Cancer Forum.

Lung Cancer. 2015 Feb;87(2):186-92. doi: 10.1016/j.lungcan.2014.11.012. Epub 2014 Nov 29.

PMID:
25498829
20.

Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC.

PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.

21.

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C.

PLoS Biol. 2014 Jul 8;12(7):e1001906. doi: 10.1371/journal.pbio.1001906. eCollection 2014 Jul.

22.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J.

Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19.

PMID:
24954781
23.

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

Khan F, Ottensmeier C, Popat S, Dua D, Dorey N, Ellis S, Szabo M, Upadhyay S, Califano R, Chan S, Lee L, Ali CW, Nicolson M, Bates AT, Button M, Chaudhuri A, Mulvenna P, Shaw HM, Danson SJ.

Eur J Cancer. 2014 Jul;50(10):1717-1721. doi: 10.1016/j.ejca.2014.03.001. Epub 2014 Apr 10.

PMID:
24726055
24.

Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment.

Grose D, Morrison DS, Devereux G, Jones R, Sharma D, Selby C, Docherty K, McIntosh D, Louden G, Nicolson M, McMillan DC, Milroy R; Scottish Lung Cancer Forum.

Postgrad Med J. 2014 Jun;90(1064):305-10. doi: 10.1136/postgradmedj-2013-132186. Epub 2014 Mar 27.

PMID:
24676985
25.

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S; Panel Members; ESMO.

Ann Oncol. 2014 Aug;25(8):1475-84. doi: 10.1093/annonc/mdu123. Epub 2014 Mar 25.

26.

Exploring patterns of recurrent melanoma in Northeast Scotland to inform the introduction a digital self-examination intervention.

Auckland R, Wassell P, Hall S, Nicolson MC, Murchie P.

BMC Dermatol. 2014 Mar 11;14:4. doi: 10.1186/1471-5945-14-4.

27.

Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.

Urquhart G, Kerr KM, Nicolson M, Loo PS, Sharma R, Shrimali R, Petty RD.

J Thorac Oncol. 2013 Dec;8(12):1502-9. doi: 10.1097/JTO.0000000000000016.

28.

Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response.

Grose D, Devereux G, Brown L, Jones R, Sharma D, Selby C, Morrison DS, Docherty K, McIntosh D, McElhinney P, Nicolson M, McMillan DC, Milroy R.

Lung Cancer Int. 2014;2014:731925. doi: 10.1155/2014/731925. Epub 2014 Mar 5.

29.

Improving care for patients with lung cancer in the UK.

Sethi T, Lim E, Peake M, Field J, White J, Nicolson M, Faivre-Finn C, Cane P, Reynolds J, Møller H, Pinnock H.

Thorax. 2013 Dec;68(12):1181-5. doi: 10.1136/thoraxjnl-2013-204588. No abstract available.

PMID:
24204006
30.

Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.

Lal R, Bourayou N, Hillerdal G, Nicolson M, Vikstrom A, Lorenzo M, D'yachkova Y, Barriga S, Visseren-Grul C.

Health Qual Life Outcomes. 2013 Oct 3;11:163. doi: 10.1186/1477-7525-11-163.

31.

Prognostic factors in resected lung carcinomas.

Kerr KM, Nicolson MC.

EJC Suppl. 2013 Sep;11(2):137-49. doi: 10.1016/j.ejcsup.2013.07.023. Review. No abstract available.

32.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

33.

A rare cause of pleural disease.

Haja Mydin H, Currie GP, Denison AR, Nicolson M, Kerr KM, Srivastava P.

QJM. 2013 Jun;106(6):571-2. doi: 10.1093/qjmed/hct069. Epub 2013 Mar 13. No abstract available.

PMID:
23487832
34.

Reducing the time before consulting with symptoms of lung cancer: a randomised controlled trial in primary care.

Smith S, Fielding S, Murchie P, Johnston M, Wyke S, Powell R, Devereux G, Nicolson M, Macleod U, Wilson P, Ritchie L, Lee AJ, Campbell NC.

Br J Gen Pract. 2013 Jan;63(606):e47-54. doi: 10.3399/bjgp13X660779.

35.

Editor's snapshot: an unexpected duodenal finding.

Nelson AD, Bain GH, Graham AD, Nicolson MC, Leeds JS.

Gut. 2013 Nov;62(11):1590, 1601. doi: 10.1136/gutjnl-2012-303881. Epub 2012 Nov 10. No abstract available.

PMID:
23144075
36.

Developing a complex intervention to reduce time to presentation with symptoms of lung cancer.

Smith SM, Murchie P, Devereux G, Johnston M, Lee AJ, Macleod U, Nicolson MC, Powell R, Ritchie LD, Wyke S, Campbell NC.

Br J Gen Pract. 2012 Sep;62(602):e605-15. doi: 10.3399/bjgp12X654579.

37.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL.

Br J Cancer. 2012 Jul 24;107(3):435-41. doi: 10.1038/bjc.2012.286. Epub 2012 Jul 5.

38.

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.

Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1619-28. doi: 10.1007/s00280-011-1732-7. Epub 2011 Sep 28.

39.

Death and Doctor Hornbook by Robert Burns: a view from medical history.

Nicolson M.

Med Humanit. 2010 Jun;36(1):23-6.

PMID:
21513087
40.

Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centers.

Grose D, Devereux G, Brown L, Jones R, Sharma D, Selby C, Morrison DS, Docherty K, McIntosh D, Louden G, Downer P, Nicolson M, Milroy R; Scottish Lung Cancer Forum.

J Thorac Oncol. 2011 Mar;6(3):500-9. doi: 10.1097/JTO.0b013e318206dc10.

41.

A comparison between clinical decisions made about lung cancer patients and those inherent in the corresponding Scottish Intercollegiate Guidelines Network (SIGN) guideline.

Sleeman D, Moss L, Gyftodimos E, Nicolson M, Devereux G.

Health Informatics J. 2010 Dec;16(4):260-73. doi: 10.1177/1460458210380520.

PMID:
21216806
42.

Using bevacizumab to treat metastatic cancer: UK consensus guidelines.

Miles D, Bridgewater J, Ellis P, Harrison M, Nathan P, Nicolson M, Raouf S, Wheatley D, Plummer C.

Br J Hosp Med (Lond). 2010 Dec;71(12):670-7. Erratum in: Br J Hosp Med (Lond). 2011 Feb;72(2):115.

PMID:
21135762
43.

Improving medical students' attitudes towards the chronic sick: a role for social science research.

Mullen K, Nicolson M, Cotton P.

BMC Med Educ. 2010 Nov 22;10:84. doi: 10.1186/1472-6920-10-84.

44.

A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.

Blackhall FH, O'brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N.

J Thorac Oncol. 2010 Aug;5(8):1285-8. doi: 10.1097/JTO.0b013e3181e3a2d1.

45.

Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial.

Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC.

Br J Cancer. 2010 May 11;102(10):1447-55. doi: 10.1038/sj.bjc.6605638.

46.

Inaccurate clinical nodal staging of non-small cell lung cancer: evidence from the MRC LU22 multicentre randomised trial.

Navani N, Nankivell M, Stephens RJ, Parmar MK, Gilligan D, Nicolson M, Groen HJ, van Meerbeeck JP.

Thorax. 2010 May;65(5):463. doi: 10.1136/thx.2009.118471. No abstract available.

PMID:
20435873
47.

F-18-FDG and C-11-Choline Positron Emission Tomography in Human Esophago-Gastric Cancer: Prediction of Response to Therapy.

Suttie S, McAteer D, Sheehan M, Nicolson M, Schweiger L, Hammonds S, Smith T, Welch A, Park K.

World J Oncol. 2010 Apr;1(2):66-67. doi: 10.4021/wjon2010.04.201w. Epub 2010 Apr 30.

48.

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.

Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM.

J Thorac Oncol. 2010 Apr;5(4):442-7. doi: 10.1097/JTO.0b013e3181d40fac.

49.

Quantitative analysis of tumor in bronchial biopsy specimens.

Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, Kerr KM.

J Thorac Oncol. 2010 Apr;5(4):448-52. doi: 10.1097/JTO.0b013e3181ca12c4.

50.

James Willocks and the innovation of fetal cephalometry.

Nicolson M, Fleming JE.

Scott Med J. 2009 Nov;54(4):38-41.

PMID:
20034281

Supplemental Content

Loading ...
Support Center